193 related articles for article (PubMed ID: 24312302)
1. Dendritic cell-specific delivery of Flt3L by coronavirus vectors secures induction of therapeutic antitumor immunity.
Perez-Shibayama C; Gil-Cruz C; Nussbacher M; Allgäuer E; Cervantes-Barragan L; Züst R; Ludewig B
PLoS One; 2013; 8(11):e81442. PubMed ID: 24312302
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
3. Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.
Hennies CM; Reboulet RA; Garcia Z; Nierkens S; Wolkers MC; Janssen EM
Clin Exp Immunol; 2011 Mar; 163(3):381-91. PubMed ID: 21235535
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity.
Cervantes-Barragan L; Züst R; Maier R; Sierro S; Janda J; Levy F; Speiser D; Romero P; Rohrlich PS; Ludewig B; Thiel V
mBio; 2010 Sep; 1(4):. PubMed ID: 20844609
[TBL] [Abstract][Full Text] [Related]
5. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral injection of dendritic cells transduced by an SV40-based vector expressing interleukin-15 induces curative immunity mediated by CD8+ T lymphocytes and NK cells.
Vera M; Razquin N; Prieto J; Melero I; Fortes P; González-Aseguinolaza G
Mol Ther; 2005 Nov; 12(5):950-9. PubMed ID: 15921960
[TBL] [Abstract][Full Text] [Related]
7. Combined TLR stimulation with Pam3Cys and Poly I: C enhances Flt3-ligand dendritic cell activation for tumor immunotherapy.
Lim SN; Kuhn S; Hyde E; Ronchese F
J Immunother; 2012; 35(9):670-9. PubMed ID: 23090076
[TBL] [Abstract][Full Text] [Related]
8. Combined mobilization and stimulation of tumor-infiltrating dendritic cells and natural killer cells with Flt3 ligand and IL-18 in vivo induces systemic antitumor immunity.
Saito T; Takayama T; Osaki T; Nagai S; Suzuki T; Sato M; Kuwano H; Tahara H
Cancer Sci; 2008 Oct; 99(10):2028-36. PubMed ID: 19016763
[TBL] [Abstract][Full Text] [Related]
9. Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine.
Yo YT; Hsu KF; Shieh GS; Lo CW; Chang CC; Wu CL; Shiau AL
Cancer Gene Ther; 2007 Nov; 14(11):904-17. PubMed ID: 17704754
[TBL] [Abstract][Full Text] [Related]
10. IL-33 drives the antitumor effects of dendritic cells via the induction of Tc9 cells.
Liu N; Jiang Y; Chen J; Nan H; Zhao Y; Chu X; Wang A; Wang D; Qin T; Gao S; Yi Q; Yue Y; Wang S
Cell Mol Immunol; 2019 Jul; 16(7):644-651. PubMed ID: 30275536
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 inhibits FMS-like tyrosine kinase 3 receptor ligand (flt3L)-dependent development and function of conventional and plasmacytoid dendritic cells.
Lau-Kilby AW; Kretz CC; Pechhold S; Price JD; Dorta S; Ramos H; Trinchieri G; Tarbell KV
Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2408-13. PubMed ID: 21262836
[TBL] [Abstract][Full Text] [Related]
12. Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.
Mineharu Y; King GD; Muhammad AK; Bannykh S; Kroeger KM; Liu C; Lowenstein PR; Castro MG
Clin Cancer Res; 2011 Jul; 17(14):4705-18. PubMed ID: 21632862
[TBL] [Abstract][Full Text] [Related]
13. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells.
Okada N; Saito T; Masunaga Y; Tsukada Y; Nakagawa S; Mizuguchi H; Mori K; Okada Y; Fujita T; Hayakawa T; Mayumi T; Yamamoto A
Cancer Res; 2001 Nov; 61(21):7913-9. PubMed ID: 11691812
[TBL] [Abstract][Full Text] [Related]
14. The expression of the soluble isoform of hFlt3 ligand by recombinant vaccinia virus enhances immunogenicity of the vector.
Zurkova K; Babiarova K; Hainz P; Krystofova J; Kutinova L; Otahal P; Nemeckova S
Oncol Rep; 2009 May; 21(5):1335-43. PubMed ID: 19360312
[TBL] [Abstract][Full Text] [Related]
15. Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice.
Moran TP; Burgents JE; Long B; Ferrer I; Jaffee EM; Tisch RM; Johnston RE; Serody JS
Vaccine; 2007 Sep; 25(36):6604-12. PubMed ID: 17675184
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming.
Sánchez-Paulete AR; Teijeira Á; Quetglas JI; Rodríguez-Ruiz ME; Sánchez-Arráez Á; Labiano S; Etxeberria I; Azpilikueta A; Bolaños E; Ballesteros-Briones MC; Casares N; Quezada SA; Berraondo P; Sancho D; Smerdou C; Melero I
Cancer Res; 2018 Dec; 78(23):6643-6654. PubMed ID: 30297531
[TBL] [Abstract][Full Text] [Related]
17. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model.
Tillman BW; Hayes TL; DeGruijl TD; Douglas JT; Curiel DT
Cancer Res; 2000 Oct; 60(19):5456-63. PubMed ID: 11034088
[TBL] [Abstract][Full Text] [Related]
18. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity.
Lapteva N; Aldrich M; Weksberg D; Rollins L; Goltsova T; Chen SY; Huang XF
J Immunother; 2009; 32(2):145-56. PubMed ID: 19238013
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant Screen Identifies Synthetic DNA-Encoding Flt3L and CD80 Immunotherapeutics as Candidates for Enhancing Anti-tumor T Cell Responses.
Thorne AH; Malo KN; Wong AJ; Nguyen TT; Cooch N; Reed C; Yan J; Broderick KE; Smith TRF; Masteller EL; Humeau L
Front Immunol; 2020; 11():327. PubMed ID: 32161596
[TBL] [Abstract][Full Text] [Related]
20. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity.
Xia D; Li F; Xiang J
Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
